• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Neurogene Inc.

    2/14/25 4:00:42 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGNE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Neurogene Inc.

    (Name of Issuer)


    Common Stock, $0.000001 par value

    (Title of Class of Securities)


    64135M105

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    64135M105


    1Names of Reporting Persons

    Casdin Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,295,361.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,295,361.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,295,361.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    64135M105


    1Names of Reporting Persons

    Casdin Partners Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,075,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,075,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,075,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    64135M105


    1Names of Reporting Persons

    Casdin Partners GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,075,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,075,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,075,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    64135M105


    1Names of Reporting Persons

    Eli Casdin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,295,361.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,295,361.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,295,361.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Neurogene Inc.
    (b)Address of issuer's principal executive offices:

    535 W 24th Street, 5th Floor, New York, NY 10011
    Item 2. 
    (a)Name of person filing:

    Casdin Capital, LLC Casdin Partners Master Fund, L.P. Casdin Partners GP, LLC Eli Casdin
    (b)Address or principal business office or, if none, residence:

    Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 Casdin Partners Master Fund, L.P. 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 Casdin Partners GP, LLC 1350 Avenue of the Americas, Suite 2600 New York, New York 10019 Eli Casdin 1350 Avenue of the Americas, Suite 2600 New York, New York 10019
    (c)Citizenship:

    Casdin Capital, LLC - Delaware Casdin Partners Master Fund, L.P. - Cayman Islands Casdin Partners GP, LLC - Delaware Eli Casdin - United States
    (d)Title of class of securities:

    Common Stock, $0.000001 par value
    (e)CUSIP No.:

    64135M105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Casdin Capital, LLC - 1,295,361 Casdin Partners Master Fund, L.P. - 1,075,000 Casdin Partners GP, LLC - 1,075,000 Eli Casdin - 1,295,361
    (b)Percent of class:

    Casdin Capital, LLC - 8.7% Casdin Partners Master Fund, L.P. - 7.2% Casdin Partners GP, LLC - 7.2% Eli Casdin - 8.7%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Casdin Capital, LLC - 0 Casdin Partners Master Fund, L.P. - 0 Casdin Partners GP, LLC - 0 Eli Casdin - 0

     (ii) Shared power to vote or to direct the vote:

    Casdin Capital, LLC - 1,295,361 Casdin Partners Master Fund, L.P. - 1,075,000 Casdin Partners GP, LLC - 1,075,000 Eli Casdin - 1,295,361

     (iii) Sole power to dispose or to direct the disposition of:

    Casdin Capital, LLC - 0 Casdin Partners Master Fund, L.P. - 0 Casdin Partners GP, LLC - 0 Eli Casdin - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Casdin Capital, LLC - 1,295,361 Casdin Partners Master Fund, L.P. - 1,075,000 Casdin Partners GP, LLC - 1,075,000 Eli Casdin - 1,295,361

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G are directly owned by advisory clients of Casdin Capital, LLC. None of those advisory clients, other than Casdin Partners Master Fund, L.P., may be deemed to beneficially own more than 5% of the Common Stock, $0.000001 par value.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Casdin Capital, LLC
     
    Signature:By: /s/ Eli Casdin
    Name/Title:Eli Casdin / Managing Member
    Date:02/14/2025
     
    Casdin Partners Master Fund, L.P.
     
    Signature:By: /s/ Eli Casdin
    Name/Title:Eli Casdin / Managing Member of its General Partner
    Date:02/14/2025
     
    Casdin Partners GP, LLC
     
    Signature:By: /s/ Eli Casdin
    Name/Title:Eli Casdin / Managing Member
    Date:02/14/2025
     
    Eli Casdin
     
    Signature:By: /s/ Eli Casdin
    Name/Title:Eli Casdin
    Date:02/14/2025

    Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
    Exhibit Information

    Exhibit A - Joint Filing Agreement

    Get the next $NGNE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NGNE

    DatePrice TargetRatingAnalyst
    6/17/2025$50.00Buy
    Craig Hallum
    5/16/2025$24.00Outperform → Neutral
    Robert W. Baird
    6/27/2024$65.00Outperform
    BMO Capital Markets
    6/11/2024$54.00Outperform
    Robert W. Baird
    4/29/2024$46.00Outperform
    Leerink Partners
    3/21/2024$61.00Outperform
    William Blair
    More analyst ratings

    $NGNE
    SEC Filings

    View All

    Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neurogene Inc. (0001404644) (Filer)

    1/12/26 7:00:59 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Neurogene Inc. (0001404644) (Filer)

    11/13/25 5:11:08 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Neurogene Inc.

    10-Q - Neurogene Inc. (0001404644) (Filer)

    11/13/25 4:55:25 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurogene to Participate in Upcoming Investor Conferences

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference Format: Management will participate in a fireside chat and investor meetings Date: Wednesday, March 4 at 10:30 a.m. ET Leerink Global Healthcare Conference Format: Management will participate in a fireside chat and investor

    2/5/26 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the "Inducement Grant") on February 2, 2026 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Ru

    2/4/26 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

    Dosed multiple participants in Embolden™ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 Plan to present interim data on pediatric and adolescent/adult cohorts from Phase 1/2 trial in mid-2026 Early commercial-readiness activities underway Neurogene to present at J.P. Morgan Healthcare Conference on January 14 at 7:30 a.m. PT Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for mul

    1/12/26 7:00:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baffi Robert

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:42 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Robert Keith

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:13 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Palekar Rohan

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:06:44 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Neurogene with a new price target

    Craig Hallum initiated coverage of Neurogene with a rating of Buy and set a new price target of $50.00

    6/17/25 8:10:28 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00

    5/16/25 8:03:18 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets initiated coverage on Neurogene with a new price target

    BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

    6/27/24 7:50:19 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Samsara Biocapital Gp, Llc bought $1,259,623 worth of shares (48,770 units at $25.83) (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/27/24 4:39:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Cvijic Christine Mikail bought $491,400 worth of shares (24,000 units at $20.48), increasing direct ownership by 45% to 76,844 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mcminn Rachel bought $969,000 worth of shares (47,500 units at $20.40), increasing direct ownership by 4% to 1,297,859 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:04 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Leadership Updates

    Live Leadership Updates

    View All

    Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

    11/18/24 6:45:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

    Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom

    3/18/24 4:14:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurogene Inc.

    SC 13G - Neurogene Inc. (0001404644) (Subject)

    12/11/24 4:05:09 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/27/24 4:25:10 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/14/24 4:53:08 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Financials

    Live finance-specific insights

    View All

    Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

    11/11/24 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

    Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

    10/21/24 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care